Literature DB >> 28050139

Report from the 17th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Edmonton, Alberta; 11-12 September 2015.

K E Mulder1, S Ahmed2, J D Davies3, C M Doll1, S Dowden1, S Gill3, V Gordon4, P Hebbard4, H Lim3, A McFadden3, J P McGhie3, J Park4, R Wong4.   

Abstract

The 17th annual Western Canadian Gastrointestinal Cancer Consensus Conference (wcgccc) was held in Edmonton, Alberta, 11-12 September 2015. The wcgccc is an interactive multidisciplinary conference attended by health care professionals from across Western Canada (British Columbia, Alberta, Saskatchewan, and Manitoba) who are involved in the care of patients with gastrointestinal cancer. Surgical, medical, and radiation oncologists; pathologists; radiologists; and allied health care professionals participated in presentation and discussion sessions for the purposes of developing the recommendations presented here. This consensus statement addresses current issues in the management of gastric cancer.

Entities:  

Keywords:  Gastric cancer; chemotherapy; neoadjuvant therapy; radiation; stomach cancer; surgery

Year:  2016        PMID： 28050139      PMCID： PMC5176376          DOI： 10.3747/co.23.3384

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


  109 in total

1.  Classification of regional lymph node metastasis from gastric carcinoma. German Gastric Cancer Study Group.

Authors:  J D Roder; K Böttcher; R Busch; C Wittekind; P Hermanek; J R Siewert
Journal:  Cancer       Date:  1998-02-15       Impact factor: 6.860

2.  Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Authors:  Peter C Thuss-Patience; Albrecht Kretzschmar; Dmitry Bichev; Tillman Deist; Axel Hinke; Kirstin Breithaupt; Yasemin Dogan; Bernhard Gebauer; Guido Schumacher; Peter Reichardt
Journal:  Eur J Cancer       Date:  2011-10       Impact factor: 9.162

Review 3.  Gastric cancer: global pattern of the disease and an overview of environmental risk factors.

Authors:  D Forman; V J Burley
Journal:  Best Pract Res Clin Gastroenterol       Date:  2006       Impact factor: 3.043

4.  Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants.

Authors:  H Gille; J Kowalski; B Li; J LeCouter; B Moffat; T F Zioncheck; N Pelletier; N Ferrara
Journal:  J Biol Chem       Date:  2000-10-31       Impact factor: 5.157

Review 5.  Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.

Authors:  Anna D Wagner; Wilfried Grothe; Johannes Haerting; Gerhard Kleber; Axel Grothey; Wolfgang E Fleig
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

6.  Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.

Authors:  Jung Hun Kang; Soon Il Lee; Do Hyoung Lim; Keon-Woo Park; Sung Yong Oh; Hyuk-Chan Kwon; In Gyu Hwang; Sang-Cheol Lee; Eunmi Nam; Dong Bok Shin; Jeeyun Lee; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang; Se Hoon Park
Journal:  J Clin Oncol       Date:  2012-03-12       Impact factor: 44.544

Review 7.  Hereditary diffuse gastric cancer: What the clinician should know.

Authors:  Ryan Ying Cong Tan; Joanne Ngeow
Journal:  World J Gastrointest Oncol       Date:  2015-09-15

8.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Authors:  Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

9.  Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.

Authors:  Shuichi Hironaka; Shinya Ueda; Hirofumi Yasui; Tomohiro Nishina; Masahiro Tsuda; Takehiko Tsumura; Naotoshi Sugimoto; Hideki Shimodaira; Shinya Tokunaga; Toshikazu Moriwaki; Taito Esaki; Michitaka Nagase; Kazumasa Fujitani; Kensei Yamaguchi; Takashi Ura; Yasuo Hamamoto; Satoshi Morita; Isamu Okamoto; Narikazu Boku; Ichinosuke Hyodo
Journal:  J Clin Oncol       Date:  2013-11-04       Impact factor: 44.544

10.  Prophylactic total gastrectomy (PTG) for hereditary diffuse gastric cancer (HDGC): the Newfoundland experience with 23 patients.

Authors:  P C Hebbard; A Macmillan; D Huntsman; P Kaurah; F Carneiro; X Wen; A Kwan; D Boone; F Bursey; J Green; B Fernandez; D Fontaine; D A Wirtzfeld
Journal:  Ann Surg Oncol       Date:  2009-05-01       Impact factor: 5.344
View more
  1 in total

1.  Real-world treatment attrition rates in advanced esophagogastric cancer.

Authors:  Erica S Tsang; Howard J Lim; Daniel J Renouf; Janine M Davies; Jonathan M Loree; Sharlene Gill
Journal:  World J Gastroenterol       Date:  2020-10-21       Impact factor: 5.742
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.